Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Introduction: The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer's disease (AD). AMYPAD PNHS adds (semi‐)quantitative amyloid PET imaging to several European parent cohorts (PCs) to predict AD‐related progression as well as address methodological challenges in amyloid PET. Methods: AMYPAD PNHS is an open‐label, prospective, multi‐center, cohort study recruiting from multiple PCs. Around 2000 participants will undergo baseline amyloid positron emission tomography (PET), half of whom will be invited for a follow‐up PET 12 at least 12 months later. Results: Primary include several amyloid PET measurements (Centiloid, SUVr, BP ND, R 1), and secondary are their changes from baseline, relationship to other amyloid markers (cerebrospinal fluid and visual assessment), and predictive value of AD‐related decline. Expected Impact: Determining the role of amyloid PET for the understanding of this complex disease and potentially improving secondary prevention trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Alzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685
Donohue, M. C., Sperling, R. A., Petersen, R., Sun, C.-K., Weiner, M. W., Aisen, P. S., & Initiative, F. T. A. D. N. (2017) · JAMA · doi:10.1001/jama.2017.6669 · Cited by 452
In vivo staging of regional amyloid deposition
Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004643 · Cited by 440
Cited by
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226
“Assess value of quantification to improve risk stratification and individualised disease trajectory in the earliest stages of AD Primary outcome of the PNHS [51]”
BackgroundMethodInfluentialSelf-citationEarly detection of amyloid load using 18F-florbetaben PET
Bullich, S., Roé-Vellvé, N., Marquié, M., Landau, S. M., Barthel, H., Villemagne, V. L., Sanabria, Á., Tartari, J. P., Sotolongo-Grau, O., Doré, V., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00807-6 · Cited by 71
Self-citationRegional associations of white matter hyperintensities and early cortical amyloid pathology
Lorenzini, L., Ansems, L. T., Lopes Alves, I., Ingala, S., Vállez García, D., Tomassen, J., Sudre, C., Salvadó, G., Shekari, M., Operto, G., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac150 · Cited by 36
Self-citationCollij, L. E., Mastenbroek, S. E., Salvadó, G., Wink, A. M., Visser, P. J., Barkhof, F., van Berckel, B. N. M., & Lopes Alves, I. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12216 · Cited by 17
Self-citationOsset-Malla, M., Martínez-Velasco, A., Sánchez-Benavides, G., Buongiorno, M., de la Sierra, A., Shekari, M., Minguillon, C., Kollmorgen, G., Quijano-Rubio, C., Zetterberg, H., et al. (2025) · The Journal of Prevention of Alzheimer's Disease · doi:10.1016/j.tjpad.2025.100304 · Cited by 8
“CL quantification was performed following harmonized procedures across centers [26].”
Self-citationYu, Y., Fedele, G., Celardo, I., Zhou, L., Zhi Tan, B. W., Loh, S. H. Y., & Martins, L. M. (2025) · doi:10.1101/2025.02.26.640405 · Cited by 3
Metadata
- Authors
- Lopes Alves, I., Collij, L. E., Altomare, D., Frisoni, G. B., Saint‐Aubert, L., Payoux, P., Kivipelto, M., Jessen, F., Drzezga, A., Leeuwis, A., Wink, A. M., Visser, P. J., van Berckel, B. N. M., Scheltens, P., Gray, K. R., Wolz, R., Stephens, A., Gismondi, R., Buckely, C., Gispert, J. D., Schmidt, M., Ford, L., Ritchie, C., Farrar, G., Barkhof, F., Molinuevo, J. L., & the AMYPAD Consortium
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2020-04-12
- Volume
- 16
- Issue
- 5
- Pages
- 750-758
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W3015893323
- Cited by
- 67
- References
- 16
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.